search
Company Information
USD
92.77
- (-2.1%)
NASDAQ:BNTX, BIONTECH SE
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

Address

An der Goldgrube 12

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Dr. Ulrich Wandschneider
Deputy Chairman/Director
Mr. Helmut Jeggle
Chairman of the Board/Director
Mr. Jens Holstein
CFO
Professor Ugur Sahin, M.D.
CEO/Co-Founder
Mr. Sean Marett
Other Executive Officer
Dr. Sierk Poetting
COO
Dr. Ozlem Tureci
Chief Medical Officer
Mr. Michael Motschmann
Director
Professor Christoph Huber, M.D.
Director
Mr. Ryan Richardson
Chief Strategy Officer
Professor Rudolf Staudigl
Director
Professor Anja Morawietz
Director

Ownership

Institution Holdings

Baillie Gifford & Co Limited.
8,689,182 (3.655%)
PRIMECAP Management Company
4,763,453 (2.004%)
Temasek Holdings Ltd.
4,518,080 (1.901%)
Harding Loevner L.P.
3,944,474 (1.659%)
Flossbach von Storch AG
3,548,660 (1.493%)
Harding Loevner LP
2,292,988 (0.965%)
BlackRock Inc
1,640,016 (0.690%)
BlackRock Fund Advisors
1,398,501 (0.588%)
UBS Asset Mgmt Americas Inc
995,253 (0.419%)
Capital World Investors
938,747 (0.395%)

Funds Holdings

Vanguard Capital Opportunity Fund
2,357,736 (0.992%)
PrimeCap Odyssey Aggressive Growth Fund
1,361,752 (0.573%)
iShares Biotechnology ETF
1,347,974 (0.567%)
Baillie Gifford WW Long Term Glbl Gr Fd
677,492 (0.285%)
Baillie Gifford L/T Glb Gr Invmt Fd
486,134 (0.205%)
PrimeCap Odyssey Growth Fund
418,700 (0.176%)
ACATIS Datini Valueflex Fonds
280,000 (0.118%)
DWS ESG Dynamic Opportunities
245,448 (0.103%)
AustralianSuper Balanced
228,106 (0.096%)
Baron Focused Growth Strategy
200,000 (0.084%)

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow
Make Smart Investment Choices